Why Tharimmune (THAR) Shares Are Getting Hammered
Why Tharimmune (THAR) Shares Are Getting Hammered
Tharimmune Inc (NASDAQ:THAR) shares are trading lower by 30% to $3.60 during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement with Rodman & Renshaw LLC for the sale of up to $1.65 million worth of its common stock through the sales agent.
在週一的交易中，Tharimmune Inc (納斯達克股票代碼: THAR) 的股票下跌了30%，跌至3.60美元。公司上週五宣佈已與Rodman＆Renshaw LLC簽訂了“市場價”銷售協議，通過銷售代理銷售價值高達165萬美元的普通股。
The stock is listed on Nasdaq under the symbol "THAR," with a last reported price of $5.17 per share on June 5, 2024. The sales agent will sell shares using commercially reasonable efforts and is entitled to a 3% commission on the gross proceeds. They may also purchase shares as a principal under separately negotiated terms.
該股票在納斯達克上市，股票代碼爲“THAR”，上次報告的價格爲2024年6月5日每股5.17美元。銷售代理將盡商業上的合理努力銷售股票，並有權獲得總收益的3%作爲佣金。他們還可以根據獨立協商的條款作爲負責人購買股票。
As a smaller reporting and emerging growth company, the company benefits from reduced public disclosure standards. The aggregate market value of its common stock held by non-affiliates is approximately $5.1 million, based on 786,031 outstanding shares.
作爲一家較小的上市公司和新興成長型企業，該公司受益於較低的公開信息披露標準。基於786,031股股份，其非附屬股東持有的普通股的總市值約爲510萬美元。
According to regulatory limits, the company cannot sell securities exceeding one-third of this value in a 12-month period, provided the aggregate market value remains under $75 million. No shares have been sold under these terms in the past 12 months.
根據監管限制，公司不能在12個月內銷售超過該價值的三分之一的證券，前提是總市值仍然低於7500萬美元。在過去的12個月中，未按這些條款出售任何股票。
Should I Sell My THAR Stock?
我應該賣出我的THAR股票嗎？
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
是否賣出或持有某隻股票在很大程度上取決於投資者的策略和風險承受能力。波段交易者可以賣出表現良好的股票以鎖定資本收益，而長期投資者可能會在預期進一步股價增長的情況下忍受波動。
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
同樣，願意將損失最小化的交易者可能會出售下跌一定百分比的股票，而長期投資者則可能會將其視爲以折扣價買入更多股票的機會。
Shares of Tharimmune have lost 97.58% year to date. This compares to the average annual return of -84.15%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
Tharimmune的股票今年迄今爲止已經下跌了97.58%。這與平均年回報率-84.15%相比，意味着該股票表現低於其歷史平均水平。投資者可以將一隻股票的走勢與其歷史表現進行比較，以衡量這是否是正常的走勢或潛在的交易機會。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Tharimmune stock currently has an RSI of 73.95, indicating overbought conditions.
投資者還可以考慮市場動態。相對強弱指數可以用來指示股票是否超買或超賣。Tharimmune的股票目前的RSI爲73.95，表明處於超買狀態。
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
欲獲取分析工具、圖表數據和獨家股票新聞，請登錄Benzinga PRO。現在免費試用。
THAR has a 52-week high of $142.50 and a 52-week low of $3.50.
THAR的52周最高股價爲142.50美元，52周最低股價爲3.50美元。
譯文內容由第三人軟體翻譯。